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Abstract: Hepatocellular carcinoma (HCC) is sexually dimorphic in
both rodents and humans, with signiﬁcantly higher incidence in
males, an effect that is dependent on sex hormones. The molecular
mechanisms by which estrogens prevent and androgens promote
liver cancer remain unclear. Here, we discover that sexually dimor-
phic HCC is completely reversed in Foxa1- and Foxa2-deﬁcient mice
after diethylnitrosamine-induced hepatocarcinogenesis. Coregula-
tion of target genes by Foxa1/a2 and either the estrogen receptor
(ERa) or the androgen receptor (AR) was increased during hepato-
carcinogenesis in normal female or male mice, respectively, but
was lost in Foxa1/2-deﬁcient mice. Thus, both estrogen-dependent
resistance to and androgen-mediated facilitation of HCC depend on
Foxa1/2. Strikingly, single nucleotide polymorphisms at FOXA2 bind-
ing sites reduce binding of both FOXA2 and ERa to their targets in
human liver and correlate with HCC development in women. Thus,
Foxa factors and their targets are central for the sexual dimorphism
of HCC. 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Despite recent breakthroughs in the management of hepato-
cellular carcinoma (HCC), it is still the fastest-rising cause of can-
cer-related death in the United States [1]. Unfortunately, most
patients are diagnosed at intermediate-advanced stages, when
curative therapies are not a primary option. HCC natural history
is fairly well known, since most tumors arise from a traceable
underlying liver disease (i.e., cirrhosis), allowing for early
diagnosis in the setting of surveillance programs. In patients withJournal of Hepatology 20
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with a solid predominance for males regardless of geographic
area, etiologic factor, and ethnicity. Male to female ratio averages
between 2:1 and >4:1 across studies [2]. These discrepancies are
not merely explained by gender-speciﬁc differences in exposure
to cirrhosis risk factors (e.g., viral hepatitis or alcohol abuse),
since experimental models of chemically-induced HCC also
demonstrate a clear male predominance, although molecular
mechanisms behind gender bias remain unknown. There is also
preliminary evidence suggesting that speciﬁc genomic proﬁles,
once HCC has developed, are predominant according to patient’s
gender, reﬂected by an enrichment in certain molecular
subclasses [3,4].
In a recent study by Li et al. [5], the authors report a central
role for the winged helix transcription factors Foxa1/Foxa2 in con-
trolling estrogen and androgen signaling via the recruitment of
estrogen receptor alpha (ERa) and androgen receptor (AR) to
hepatocyte target genes. They found that the effects of sex hor-
mones in the liver are Foxa1/Foxa2-dependent and provide a
novel molecular mechanism responsible for gender dimorphism
in HCC. Sexually dimorphic HCC was completely reversed in
Foxa1- and Foxa2-deﬁcient mice after chemically-induced
(diethylnitrosamine) HCC. The authors also included human sam-
ples in their analysis, and despite the fact that no mutations in
any of the FOXA genes have been reported so far in HCC, the
authors provide evidence that certain single nucleotide polymor-
phisms at FOXA2 binding sites reduce its afﬁnity with ERa, and
this correlates with increased incidence of HCC development in
women. A similar gender bias occurrence was observed in a
recent forward genetic screen using the Sleeping Beauty transpo-
son insertional mutagenesis system [6]. Overall, the study by Li
et al. [5] reveals a novel interplay between Foxa and hormone
receptors binding sites that justiﬁes gender disparities in HCC.
Molecular data indicate that androgens contribute to the HCC
development by acting as tumor promoters via induction of DNA
damage and oxidative stress [7]. Conversely, estrogens have been
suggested to act as general suppressors of HCC through reduction
in the proinﬂammatory effects of MyD88-mediated secretion of
IL6 [8]. In addition, estrogens seem to exert different tumorigenic
properties depending on the tissue type, since contrary to the
epidemiological data in cirrhotic women, chronic exposure to
estrogens favors carcinogenesis in breast and uterus. Paradoxi-
cally, both androgens (i.e., anabolic steroids) and estrogens (e.g.,
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Fig. 1. Summary of the role of sex hormones in HCC. Different data indicate a
pro-tumorigenic role of androgens in both the cirrhotic and normal liver.
However, evidence from experimental models of chemically-induced HCC
suggests that estrogens may be protective in this setting by interfering with IL6
production and FOXA DNA binding sites.
International Hepatologyadenomas) and ultimately HCC in individuals without underlying
liver disease (Fig. 1). Overall, the effects of estrogens in terms of
cancer development are largely tissue and environment-depen-
dent, protective in experimental models of cirrhosis but inducing
oncogenesis in the normal liver, and promoting tumor growth in
full-blown HCC. Strikingly, the study by Li et al. [5] found that
tumor load in female Foxa-deﬁcient mice far exceeded that of
control males, suggesting that estrogens could have a pro-tumor-
igenic effect in the absence of Foxa1/Foxa2. Whether Foxa is the
link that explains these opposing effects of estrogens requires
further investigation. Background inﬂammation in cirrhosis could
play an additional confounding role, emphasized by the crosstalk
between IL6-STAT signaling and estrogens in experimental mod-
els of HCC [8].
From a therapeutic standpoint, several studies have tried to
evaluate the role of anti-estrogen therapy (e.g., tamoxifen) in454 Journal of Hepatology 201patients with overt HCC. Evidence of expression of ER in some
tumors and experimental data of estrogen-dependent HCC
growth provided the scientiﬁc rational for this approach. Most
of the studies were small trials, conducted in the 1990s and
including a heterogeneous patient population. A meta-analysis
including close to 700 patients revealed no impact of tamoxifen
in 1-year survival in patients with HCC [9]. Data on anti-andro-
gens or a possible role of hormone therapy in the chemo-preven-
tive scenario are even less informative.
In summary, we are at the beginning of unraveling the com-
plex molecular mechanisms behind gender disparities in HCC.
Among them, estrogens seem to play a role in IL6 production
and modulation of gene expression through FOXA transcription
factors, what prevents HCC development in experimental models
of HCC. However, more data are still needed to deﬁne the impli-
cation of sexual hormones in the molecular pathogenesis of HCC.
This could provide the proof-of-principle to rescue hormone-
based drugs for further evaluation as systemic therapies of HCC
in certain clinical contexts.
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